MARKET

PRRUF

PRRUF

Immutep Ltd
OTCPK
0.221
NaN%
Closed 09:30 05/23 EDT
OPEN
--
PREV CLOSE
0.221
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
0.273
52 WEEK LOW
0.183
MARKET CAP
322.89M
P/E (TTM)
-10.7854
1D
5D
1M
3M
1Y
5Y
1D
Immutep’s Promising Phase 1 INSIGHT-003 Results Drive Buy Rating
TipRanks · 4d ago
Weekly Report: what happened at PRRUF last week (0512-0516)?
Weekly Report · 4d ago
Canaccord Genuity Sticks to Their Buy Rating for Immutep Ltd (PRRUF)
TipRanks · 05/15 23:36
Immutep announces response rates from INSIGHT-003 trial
TipRanks · 05/15 12:21
Immutep’s Efti Combination Shows Promising Results in Lung Cancer Trial
TipRanks · 05/14 22:22
Weekly Report: what happened at PRRUF last week (0505-0509)?
Weekly Report · 05/12 09:30
Immutep Limited: Surging On Positive Head And Neck Data
Seeking Alpha · 05/08 12:46
Biotech Alert: Searches spiking for these stocks today
TipRanks · 05/07 16:15
More
About PRRUF
Immutep Limited is an Australia-based clinical-stage biotechnology company. The Company is focused on developing Lymphocyte Activation Gene (LAG)-3 immunotherapies for cancer and autoimmune diseases. Its lead product candidate, Eftilagimod alpha (efti or IMP321), is a soluble LAG-3Ig fusion protein that is an antigen-presenting cell (APC) agonist designed to capitalize on LAG-3’s ability to drive the adaptive and innate immune systems against cancer. IMP761 is an immunosuppressive agonist antibody to LAG-3, which has the potential to address the root cause of autoimmune diseases by specifically silencing autoimmune memory T cells. Its third product candidate is LAG525, an antagonist (blocking) antibody targeting the LAG-3 molecule on T cells with potential applications in the treatment of cancer. Its fourth product candidate is IMP731 (GSK 781), a depleting (cytotoxic) antibody that is intended to destroy LAG-3 expressing activated T cells involved in autoimmunity.

Webull offers Immutep Ltd stock information, including OTCPK: PRRUF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRRUF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRRUF stock methods without spending real money on the virtual paper trading platform.